With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.
5317-33-9, Preparation of 3-(4-methylpiperazin-1-yl)propan-1-yl chloroformate dihydrochloride 370 g of hydrogen chloride are passed into a solution of 712 g (4.50 mol) of 3-(4-methylpiperazin-1-yl)propan-1-ol in 8.0 l of acetonitrile with external cooling, and the suspension is stirred at room temperature for 18 hours. 1200 g (6.07 mol) of trichloromethyl chloroformate are subsequently added dropwise with cooling at an internal temperature of 2-10 C., and the resultant suspension is subsequently stirred for 3 days with gentle warming at an internal temperature of 35 C. The reaction mixture is filtered with suction, washed with 2 l of acetonitrile and 2 l of diethyl ether and dried in vacuo: 3-(4-methylpiperazin-1-yl)propan-1-yl chloroformate dihydrochloride as colourless crystals; m.p. 249 C. (decomposition).
As the paragraph descriping shows that 5317-33-9 is playing an increasingly important role.
Reference：
Patent; MERCK PATENT GESELLSCHAFT MIT BESCHRAeNKTER HAFTUNG; US2011/136819; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics